Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Cadisegliatin 800 mg QDDrug: Cadisegliatin 800 mg BIDDrug: Placebo
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT06334133
- Locations
- 🇺🇸
Scripps Whittier Diabetes Institute, La Jolla, California, United States
🇺🇸Vector Clinical Trials, Sparks, Nevada, United States
🇺🇸Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 43
- Registration Number
- NCT03980730
- Locations
- 🇺🇸
NeuroStudies.net LLC, Decatur, Georgia, United States
🇨🇦Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada
🇺🇸Tucson Neuroscience Research, Tucson, Arizona, United States
Evaluation of TTP399 in Patients With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT03335371
- Locations
- 🇺🇸
AMCR Institute, Escondido, California, United States
🇺🇸PMG Research of Wilmington, Wilmington, North Carolina, United States
🇺🇸University of Colorado Barbara Davis Center, Aurora, Colorado, United States
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 297
- Registration Number
- NCT02916056
A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 174
- Registration Number
- NCT02653599
Add Glucokinase Activator to Target A1c
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 190
- Registration Number
- NCT02405260
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 880
- Registration Number
- NCT02080364
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 186
- Registration Number
- NCT01665352
- Locations
- 🇺🇸
Site 5, Port Orange, Florida, United States
🇺🇸Site 13, Denver, Colorado, United States
🇺🇸Site 1, Los Angeles, California, United States
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT01548430
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: GK1-399 (formerly TTP399)Drug: Placebo
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 248
- Registration Number
- NCT01474083
- Locations
- 🇺🇸
Forest Investigative Site 010, Overland Park, Kansas, United States
🇺🇸Forest Investigative Site 005, Springfield, Missouri, United States
🇺🇸Forest Investigative Site 003, Neptune, New Jersey, United States